Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL

被引:24
|
作者
Artykov, Artem A. [1 ]
Yagolovich, Anne, V [1 ,2 ]
Dolgikh, Dmitry A. [1 ,2 ]
Kirpichnikov, Mikhail P. [1 ,2 ]
Trushina, Daria B. [3 ]
Gasparian, Marine E. [1 ]
机构
[1] RAS, Dept Bioengn, Inst Bioorgan Chem, Moscow, Russia
[2] Lomonosov Moscow State Univ, Fac Biol, Moscow, Russia
[3] Russian Acad Sci, Dept Xray & Synchrotron Res, AV Shubnikov Inst Crystallog Fed Sci Res Ctr Crys, Moscow, Russia
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2021年 / 9卷
基金
俄罗斯基础研究基金会; 俄罗斯科学基金会;
关键词
DR5; DR4; TRAIL; receptor endocytosis; receptor recycling; membrane traffic; brefeldin A; SURFACE EXPRESSION; APOPTOSIS; RESISTANCE; CLATHRIN; NUCLEAR; INTERNALIZATION; LOCALIZATION; TRAFFICKING; APO2L/TRAIL; SELECTIVITY;
D O I
10.3389/fcell.2021.733688
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tumor necrosis factor-associated ligand inducing apoptosis (TRAIL) induces apoptosis through the death receptors (DRs) 4 and 5 expressed on the cell surface. Upon ligand stimulation, death receptors are rapidly internalized through clathrin-dependent and -independent mechanisms. However, there have been conflicting data on the role of death receptor endocytosis in apoptotic TRAIL signaling and possible cell type-specific differences in TRAIL signaling have been proposed. Here we have compared the kinetics of TRAIL-mediated internalization and subsequent recycling of DR4 and DR5 in resistant (HT-29 and A549) and sensitive (HCT116 and Jurkat) tumor cell lines of various origin. TRAIL stimulated the internalization of both receptors in a concentration-dependent manner with similar kinetics in sensitive and resistant cell lines without affecting the steady-state expression of DR4 and DR5 in cell lysates. Using the receptor-selective TRAIL variant DR5-B, we have shown that DR5 is internalized independently of DR4 receptor. After internalization and elimination of TRAIL from culture medium, the receptors slowly return to the plasma membrane. Within 4 h in resistant or 6 h in sensitive cells, the surface expression of receptors was completely restored. Recovery of receptors occurred both from newly synthesized molecules or from trans-Golgi network, as cycloheximide and brefeldin A inhibited this process. These agents also suppressed the expression of cell surface receptors in a time- and concentration-dependent manner, indicating that DRs undergo constitutive endocytosis. Inhibition of receptor endocytosis by sucrose led to sensitization of resistant cells to TRAIL and to an increase in its cytotoxic activity against sensitive cells. Our results confirm the universal nature of TRAIL-induced death receptor endocytosis, thus cell sensitivity to TRAIL can be associated with post-endocytic events.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
    Yang, Annie
    Wilson, Nicholas S.
    Ashkenazi, Avi
    CURRENT OPINION IN CELL BIOLOGY, 2010, 22 (06) : 837 - 844
  • [22] Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells
    Wu, XX
    Kakehi, Y
    Mizutani, Y
    Nishiyama, H
    Kamoto, T
    Megumi, Y
    Ito, N
    Ogawa, O
    INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (04) : 409 - 417
  • [23] Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis
    Shishodia, Gauri
    Koul, Sweaty
    Dong, Qin
    Koul, Hari K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1217 - 1228
  • [24] Ionizing Radiation Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis through Up-Regulations of Death Receptor 4 (DR4) and Death Receptor 5 (DR5) in Human Osteosarcoma Cells
    Hori, Takeshi
    Kondo, Takashi
    Kanamori, Masahiko
    Tabuchi, Yoshiaki
    Ogawa, Ryohei
    Zhao, Qing-Li
    Ahmed, Kanwal
    Yasuda, Taketoshi
    Seki, Shoji
    Suzuki, Kayo
    Kimura, Tomoatsu
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2010, 28 (06) : 739 - 745
  • [25] Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL
    Gomez-Benito, Maria
    Martinez-Lorenzo, Maria Jose
    Anela, Alberto
    Marzo, Isabel
    Naval, Javier
    EXPERIMENTAL CELL RESEARCH, 2007, 313 (11) : 2378 - 2388
  • [26] α-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route:: Implication for sensitisation of resistant cancer cells to TRAIL apoptosis
    Tomasetti, M
    Andera, L
    Alleva, R
    Borghi, B
    Neuzil, J
    Procopio, A
    FEBS LETTERS, 2006, 580 (08) : 1925 - 1931
  • [27] RRR-γ-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling
    Yu, Weiping
    Park, Sook-Kyung
    Jia, Li
    Tiwary, Richa
    Scott, Wenjun W.
    Li, Jing
    Wang, Pei
    Simmons-Menchaca, Marla
    Sanders, Bob G.
    Kline, Kimberly
    CANCER LETTERS, 2008, 259 (02) : 165 - 176
  • [28] Apoptosis-related Factors (TRAIL, DR4, DR5, DcR1, DcR2, Apoptotic Cells) and Proliferative Activity in Ameloblastomas
    Rizzardi, Clara
    Leocata, Pietro
    Ventura, Luca
    Zweyer, Marina
    Brollo, Alessandro
    Schneider, Manuela
    Melato, Mauro
    ANTICANCER RESEARCH, 2009, 29 (04) : 1137 - 1142
  • [29] Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells
    Yan, Shunchao
    Qu, Xiujuan
    Xu, Chong'an
    Zhu, Zhitu
    Zhang, Lingyun
    Xu, Ling
    Song, Na
    Teng, Yuee
    Liu, Yunpeng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (08) : 1279 - 1289
  • [30] Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells
    Shunchao Yan
    Xiujuan Qu
    Chong’an Xu
    Zhitu Zhu
    Lingyun Zhang
    Ling Xu
    Na Song
    Yuee Teng
    Yunpeng Liu
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1279 - 1289